Tesamorelin (10mg Vial) Dosage Protocol
A stabilized GHRH analog that stimulates natural growth-hormone release and reduces visceral fat - FDA-approved (Egrifta) for HIV-associated lipodystrophy; other uses are research/educational only.
Stabilized GHRH (1-44) analog; stimulates pituitary GH release, raising IGF-1 and reducing visceral abdominal fat.
2 mg (2000 mcg) once daily subcutaneously, the FDA-approved regimen, after an optional 1 mg first-week titration.
3 mL bacteriostatic water per 10 mg vial gives ~3.33 mg/mL for accurate insulin-syringe dosing.
Refrigerate the lyophilized vial (Egrifta SV is room-temp stable); refrigerate the reconstituted solution and do not freeze it.
Looking for results? See Tesamorelin before and after — what the research actually shows (honest, research-based, no transformation photos).
Pre-filled with this protocol’s recommended BAC water and documented starting dose — edit any field to run your own numbers. Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Full reconstitution guide → · Advanced calculator →Mix & measure Tesamorelin · 10 mg
Dosing & Reconstitution Guide
A single practical dilution with accurate once-daily dosing, step by step
Standard FDA-Approved Protocol (3 mL = ~3.33 mg/mL)
Reconstitute: Add 3.0 mL bacteriostatic water to one 10 mg vial → final concentration ~3.33 mg/mL (3,333 mcg/mL).
Standard daily dose: 2 mg (2000 mcg) once daily subcutaneously — the FDA-approved regimen — with an optional 1 mg first week for tolerability.
Easy measuring: At ~3.33 mg/mL, 1 unit ≈ 33.3 mcg on a U-100 syringe, so the 2 mg dose reads at a clear 60 units.
Storage: Refrigerate the lyophilized vial at 2–8 °C (35.6–46.4 °F) (Egrifta SV is stable at room temperature); after reconstitution, refrigerate at 2–8 °C and do not freeze the mixed solution.
Why Tesamorelin draws research interest
These are the directions researchers and the peptide community most often explore Tesamorelin for — so you know you’re in the right place. They describe what is being studied, not proven benefits, approved uses, or promised results.
Visceral (abdominal) fat reduction
Its one approved use (Egrifta, for HIV-associated lipodystrophy) - studied for reducing deep abdominal fat.
Growth hormone & IGF-1 support
A GHRH analog studied for prompting the body's own growth-hormone pulses and raising IGF-1.
Body composition & metabolic research
Explored in research on lean mass, fat distribution and metabolic markers.
Healthy-aging interest
Looked into for the age-related decline in natural growth-hormone output.
Evidence ranges from early laboratory work to clinical trials depending on the use — the sections below cover the actual data and sources.
Quickstart Highlights
Tesamorelin is a synthetic, stabilized analog of growth-hormone-releasing hormone (GHRH 1-44) that prompts the pituitary to release growth hormone, raising IGF-1 and notably reducing visceral (deep abdominal) fat[1][3]. Unlike most peptides on this site, tesamorelin is FDA-approved (brand Egrifta / Egrifta SV) for one specific indication: reducing excess abdominal fat in HIV-associated lipodystrophy. Any other use is off-label or research only. This page outlines the once-daily subcutaneous approach and is presented for research and educational purposes.
Add 3.0 mL bacteriostatic water to one 10 mg vial → ~3.33 mg/mL (3,333 mcg/mL).
2 mg (2000 mcg) once daily subcutaneously — the FDA-approved regimen — after an optional 1 mg first-week titration.
At ~3.33 mg/mL, 1 unit ≈ 33.3 mcg; 1 mg ≈ 30 units and 2 mg ≈ 60 units on a U-100 syringe.
Lyophilized: refrigerate at 2–8 °C (35.6–46.4 °F) (Egrifta SV is room-temperature stable); once reconstituted, refrigerate at 2–8 °C and do not freeze.
Important: Start with the Prep & Injection Guide — it covers the preparation and safety basics every protocol on this site assumes.
Frequency: one subcutaneous injection each day, preferably in the evening to align with the body’s natural nocturnal growth-hormone release[2]. The 2 mg daily dose is the standard FDA-approved regimen for HIV-associated lipodystrophy[3][4]; a one-week titration at 1 mg may improve early tolerability.
Reconstitution Steps
Draw 3.0 mL of bacteriostatic water into a sterile syringe.
Release it slowly down the vial’s inner wall to limit foaming.
Swirl or roll gently until fully dissolved — don’t shake.
Label with the date and concentration, then refrigerate at 2–8 °C (35.6–46.4 °F), shielded from light.
The 3.0 mL dilution keeps the standard 2 mg dose at 60 units, where U-100 syringe markings are easy to read. Avoid freezing the reconstituted solution, since freeze–thaw can denature the peptide.
Important: This guide is for educational purposes only and is not medical advice. Tesamorelin is a prescription medication; any therapeutic use should be supervised by a qualified clinician.
Supplies Needed
Quantities below assume an 8–16 week course of once-daily injections at the standard 2 mg dose (after the optional Week 1 titration).
At 2 mg/day, a 10 mg vial covers about five days, so plan for roughly 1.4 vials per week.
- 8 weeks: ~11 vials
- 12 weeks: ~17 vials
- 16 weeks: ~22 vials
- Per injection: 1 syringe
- 8 weeks (once daily): ~56 syringes
- 16 weeks (once daily): ~112 syringes
Use ~3.0 mL per 10 mg vial for reconstitution.
- 8 weeks (11 vials): ~33 mL → 4 bottles
- 16 weeks (22 vials): ~66 mL → 7 bottles
One for the vial stopper + one for the injection site each day.
- Per injection: 2 swabs
- 8 weeks (once daily): ~112 swabs → 1–2 boxes
Protocol Overview
A concise summary of the FDA-approved once-daily regimen.
- ▪Goal: Reduce visceral (deep abdominal) adipose tissue and improve lipid profiles through sustained GH/IGF-1 elevation[3][4].
- ▪Schedule: Daily subcutaneous injections; clinical use typically runs 12–26 weeks and is supported up to 52 weeks under medical supervision[3].
- ▪Dose: 2 mg (2000 mcg) once daily after an optional Week 1 titration at 1 mg.
- ▪Reconstitution: 3.0 mL bacteriostatic water per 10 mg vial gives ~3.33 mg/mL for accurate unit measurements.
- ▪Storage: Refrigerate the dry vial at 2–8 °C (Egrifta SV is room-temperature stable); once mixed, refrigerate at 2–8 °C and do not freeze the solution.
Dosing Protocol
The FDA-approved daily dosing approach, with an optional tolerability titration.
- ▪Week 1 (optional): 1 mg (1000 mcg) once daily to assess tolerability.
- ▪Weeks 2+: 2 mg (2000 mcg) once daily — the standard FDA-approved dose[3][4].
- ▪Frequency: One subcutaneous injection per day, preferably in the evening.
- ▪Cycle Length: Typically 12–26 weeks; trials support up to 52 weeks with monitoring[3].
- ▪Timing: Evening administration is recommended; rotate injection sites systematically.
Storage Instructions
Correct storage is what preserves the peptide’s stability and activity.
- ▪Lyophilized: Store at 2–8 °C (35.6–46.4 °F); newer formulations (Egrifta SV) are stable at 20–25 °C (68–77 °F) before reconstitution[5].
- ▪Reconstituted (bacteriostatic water): Refrigerate at 2–8 °C (35.6–46.4 °F)[5].
- ▪Reconstituted (sterile water): Use immediately and discard any unused portion[5].
- ▪Freeze–thaw: Do not freeze the reconstituted solution, and avoid repeated freeze–thaw cycles.
Important Notes
Practical points that keep daily administration safe and consistent.
- ▪Sterile technique: Use a fresh sterile U-100 insulin syringe each time and drop it straight into a puncture-proof sharps container afterward.
- ▪Site rotation: Move between abdomen (at least 2 inches from the navel), thighs and upper arms to reduce local irritation and lipohypertrophy[6].
- ▪Metabolic monitoring: Because tesamorelin strongly stimulates GH, IGF-1 should be monitored periodically and blood glucose watched in patients with diabetes[6].
- ▪Recordkeeping: Log the daily dose, injection site and any observations to keep the protocol consistent.
- ▪Regulatory note: Tesamorelin is a prescription medication, FDA-approved (as Egrifta / Egrifta SV) only for HIV-associated lipodystrophy; any other use is off-label or research and should follow applicable law and medical supervision.
How This Works
Tesamorelin is a synthetic, stabilized analog of growth-hormone-releasing hormone (GHRH 1-44) — a 44-amino-acid peptide carrying a chemical modification that resists rapid breakdown[1].
It binds GHRH receptors on the pituitary gland, prompting the gland’s own pulsatile release of growth hormone (GH), which in turn raises circulating IGF-1[2]. Because it works through the body’s natural feedback loop rather than supplying GH directly, the GH release stays closer to a physiological pattern.
The downstream GH/IGF-1 signalling promotes lipolysis (the breakdown of stored fat) and favorable metabolic shifts. Its best-documented effect is a meaningful reduction of visceral adipose tissue — the deep abdominal fat — in people with HIV-associated lipodystrophy, alongside improved lipid profiles, over roughly 6–12 months of daily use[3][4].
Approval status: Unlike most peptides on this site, tesamorelin is FDA-approved (brand Egrifta / Egrifta SV) — but only for one specific indication: reducing excess abdominal fat in HIV-associated lipodystrophy. Other uses, such as general body-composition or anti-aging goals, are off-label or research and are presented here for educational purposes only.
Researchers also study tesamorelin for related questions — for example, reducing liver fat in NAFLD and exploring effects on age-related GH/IGF-1 decline — but those applications remain investigational[4].
Lifestyle Factors
Complementary habits that may support the protocol’s metabolic goals.
- ▪Nutrition: Favor a balanced, protein-forward diet to support the anabolic side of GH/IGF-1 signalling.
- ▪Activity: Combine resistance training with aerobic exercise to maximize fat loss and metabolic benefit.
- ▪Sleep: Aim for 7–9 hours of quality sleep to support natural GH pulsatility.
- ▪Stress: Manage stress through mindfulness or relaxation practices to support adherence and recovery.
Potential Benefits & Side Effects
Observations from clinical trials and FDA-approved use; individual results vary.
Potential Benefits
- ▪Visceral fat reduction: Meaningful reduction in visceral adipose tissue, measurable after about 3–6 months in HIV-associated lipodystrophy[3].
- ▪Lipid & liver-fat signals: Improved lipid profiles, with research interest in reducing liver fat in NAFLD[4].
- ▪Sustained tolerability: Generally well tolerated, with maintained benefits during continuous use up to 52 weeks[3].
- ▪Note on scope: Approved benefits are established for HIV-associated lipodystrophy; other uses (anti-aging, cognition) remain investigational[4].
Side Effects & Cautions
- ▪Injection-site reactions: Mild redness, itching, pain or bruising at the injection area[6].
- ▪Musculoskeletal: Joint pain (arthralgia), muscle aches and mild peripheral edema; occasional carpal-tunnel-type tingling that is dose-dependent and reversible[6].
- ▪Metabolic: IGF-1 elevation requires monitoring; small HbA1c increases have been observed in some patients[6].
- ▪Contraindications: Active malignancy (GH stimulation may accelerate latent tumors), pregnancy, and known hypersensitivity to tesamorelin or mannitol[6].
Injection Technique
General subcutaneous technique, following established clinical best-practice guidance[7][8].
Pre-Injection Preparation
- ▪Wash your hands well with soap and water.
- ▪Wipe the vial stopper with an alcohol swab and let it air-dry.
- ▪Choose a site (abdomen at least 2 inches from the navel, thigh, or upper arm) and clean it with a fresh alcohol swab, letting it dry fully[8].
- ▪Draw the intended dose, then check for air bubbles and push any out.
Injection Procedure
- ▪Pinch a skinfold at the chosen site between thumb and forefinger.
- ▪Insert the needle into the pinch at a 45–90-degree angle (use 45 degrees if the fat layer is thin)[7].
- ▪Skip aspiration for subcutaneous shots — it isn't needed[7].
- ▪Press the plunger slowly and steadily until it's fully down.
- ▪Wait 5–10 seconds, then pull the needle straight out to prevent leakage.
Post-Injection Care
- ▪Drop the used syringe straight into a puncture-proof sharps container — never recap a needle.
- ▪Return the reconstituted vial to the fridge right away.
- ▪Rotate the injection site each day to prevent irritation and lipohypertrophy[6].
- ▪Watch the site for excess redness, swelling, or signs of infection.
Recommended Source
For high-purity research peptides, we point researchers to Prime Lab Peptides for Tesamorelin (10 mg).
Why Prime Lab Peptides?
- ▪Top-rated on Trustpilot: Independently reviewed as the highest-rated peptide lab on Trustpilot — making it the best current source in the USA.
- ▪Third-party tested: Every batch ships with a Certificate of Analysis (COA) confirming purity and composition.
- ▪Consistent quality: ISO-aligned manufacturing and handling keep product integrity reliable batch to batch.
- ▪Cold-chain integrity: Temperature-controlled shipping and storage across the whole fulfilment chain.
- ▪Research-grade purity: Fit for educational and research use that demands high-quality peptides.
Note: Product availability and specifications subject to change. Verify current product details on supplier website.
References
- 1
FDA Prescribing Information (Egrifta / Egrifta SV)Tesamorelin is a stabilized synthetic analog of GHRH (1-44); approved indication, dosing and storage.
- 2
Tesamorelin (Subcutaneous route) – Drug InformationMayo Clinic / IBM Merative: mechanism, GH/IGF-1 stimulation, administration and timing.
- 3
J. Clin. Endocrinol. Metab. (2010)Effects of tesamorelin (TH9507), a GH-releasing factor analog, in HIV-infected patients with excess abdominal fat: pooled analysis of two phase 3 trials.
- 4
Safety and metabolic effects of tesamorelinLonger-term safety and metabolic effects, including visceral fat and lipid outcomes; research interest in NAFLD and aging.
- 5
Tesamorelin – LiverTox (NIH/NIDDK, 2018)Clinical and research information, including formulation storage (Egrifta vs Egrifta SV) and reconstitution handling.
- 6
Egrifta Medication Guide / NCBI BookshelfCommon adverse effects, contraindications (active malignancy, pregnancy, mannitol hypersensitivity), IGF-1 monitoring and site rotation.
- 7
Centers for Disease Control and Prevention (CDC)Subcutaneous injection technique: angle, site and no-aspiration guidance.
- 8
Subcutaneous Injection Technique (Patient Education)How to administer a subcutaneous injection: clinical technique guidelines.
Tesamorelin — frequently asked questions
How do I reconstitute a 10 mg vial of Tesamorelin?
Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units.
How much bacteriostatic water should I add to Tesamorelin?
There is no single correct amount — more water simply spreads the same 10 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units.
What do the "units" on an insulin syringe mean?
On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand.
How should I store Tesamorelin after mixing?
Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product.
How many doses does a 10 mg vial of Tesamorelin provide?
Divide the vial strength of 10 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose.
Is Tesamorelin approved for human use?
No. Tesamorelin is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.
New protocols & dosing updates
Reconstitution charts, new peptide protocols and safety updates — straight to your inbox. No spam, unsubscribe anytime.